A new study suggests that tetrahydrocannabivarin (THCV), a lesser-known compound found in cannabis, may play a role in weight loss and improving metabolic health. Researchers conducted a 90-day trial with participants who were given THCV and cannabidiol (CBD) in mucoadhesive oral strips. The results showed significant reductions in body weight, abdominal girth, systolic blood pressure, and cholesterol levels. Those who received a higher dose of THCV and CBD saw even greater benefits compared to those on a lower dose or placebo. These findings add to a growing body of research exploring how cannabinoids interact with the body’s metabolism, particularly through the endocannabinoid system, which helps regulate appetite and energy balance.

Metabolic syndrome, a condition linked to obesity, high blood pressure, and insulin resistance, affects millions of people worldwide. Traditional treatments often focus on diet, exercise, and medications, but scientists are now looking at how cannabinoids may offer additional support. THCV works differently from THC, the well-known psychoactive component of cannabis—it doesn’t create a “high” but instead acts as a CB1 receptor antagonist, meaning it may help curb appetite and encourage fat burning. When combined with CBD, which has anti-inflammatory properties, the two cannabinoids appear to work together to support metabolic health.

Participants in the study followed their normal diets and exercise routines, yet those taking THCV and CBD still experienced meaningful weight loss and health improvements. The higher-dose group lost an average of 4.1 kilograms (about nine pounds) over 90 days, while the lower-dose group lost 2.6 kilograms (about six pounds). Additionally, waist measurements decreased, a key indicator of reduced visceral fat, which is closely linked to heart disease and diabetes. These results align with earlier studies that suggest THCV can influence food intake, energy expenditure, and blood sugar regulation.

While the study was small, it provides promising evidence that cannabis-derived compounds like THCV could be useful tools for those struggling with weight management and metabolic issues. However, one unexpected finding was that some participants who took THCV tested positive for THC on drug screenings, despite not using THC-containing products. This suggests that THCV may produce metabolites that trigger standard drug tests, a consideration for those in jobs that require testing. As interest in cannabinoid-based wellness grows, future research will likely focus on refining these treatments and further exploring their benefits for metabolic health.

To learn more, sign up for our newsletter below.  To be part of the conversation, join us for our online Q&A event, Green Bridge Live!